Shock, Cardiogenic
28
5
6
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
7.1%
2 terminated out of 28 trials
85.7%
-0.8% vs benchmark
29%
8 trials in Phase 3/4
8%
1 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (28)
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care
Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock
Mobile Education and Telephone Monitoring for ICD Patients: Effects on Anxiety, Acceptance, and Self-Efficacy
Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients
ECMO LEft Ventricle UNloading Strategy
GLP-1 and Hyperoxia for Organ Protection in Heart Surgery
Hemodynamic Comparison of Peripheral and Central VA ECMO.
Impella in Cardiogenic Shock Registry
Blood Management During ECMO for Cardiac Support
Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO
Synchronized Cardiac Assist for Cardiogenic Shock
Validity of Cardiac Output Measurement Using Niccomo Device After Cardiac Surgery
Nitric Oxide in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO)
Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP
Postoperative Respiratory Abnormalities
Clinical Validation of Algorithms for Mean Systemic Filling Pressure and Automated Cardiac Output
French Observatory on the Management of Cardiogenic Shock in 2016
Validation of Epworth Richmond's Echocardiography Education Focused Year
Intraaortic Balloon Pump in Cardiogenic Shock II